Search Results - "Eng, C.M."

Refine Results
  1. 1
  2. 2
  3. 3
  4. 4

    Quantitation of anacetrapib, stable-isotope labeled-anacetrapib (microdose), and four metabolites in human plasma using liquid chromatography tandem mass spectrometry by Chavez-Eng, C.M., Lutz, R.W., Li, H., Goykhman, D., Bateman, K.P., Woolf, E.

    “…•A sensitive and selective method for the simultaneous quantitation of anacetrapib (I) and microdosed [13C515N]-anacetrapib (II) in human plasma was developed…”
    Get full text
    Journal Article
  5. 5
  6. 6

    A constitutive description of the anisotropic response of the fascia lata by Pancheri, F.Q., Eng, C.M., Lieberman, D.E., Biewener, A.A., Dorfmann, L.

    “…In this paper we propose a constitutive model to analyze in-plane extension of goat fascia lata. We first perform a histological analysis of the fascia that…”
    Get full text
    Journal Article
  7. 7

    Expanded clinical and molecular spectrum of guanidinoacetate methyltransferase (GAMT) deficiency by Dhar, S.U., Scaglia, F., Li, F.-Y., Smith, L., Barshop, B.A., Eng, C.M., Haas, R.H., Hunter, J.V., Lotze, T., Maranda, B., Willis, M., Abdenur, J.E., Chen, E., O’Brien, W., Wong, L-J.C.

    Published in Molecular genetics and metabolism (2009)
    “…Guanidinoacetate methyltransferase (GAMT) deficiency is a disorder of creatine biosynthesis, characterized by excessive amounts of guanidinoacetate in body…”
    Get full text
    Journal Article
  8. 8
  9. 9
  10. 10

    Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection by Chavez-Eng, C.M., Constanzer, M.L., Matuszewski, B.K.

    “…A method for the simultaneous determination of Aprepitant, I (5-[[2( R)-[1( R)-(3,5-bistrifluoromethylphenyl)ethoxy]-3( S)-(4-fluorophenyl)…”
    Get full text
    Journal Article
  11. 11
  12. 12

    Fabry disease: twenty novel α-galactosidase A mutations causing the classical phenotype by Ashley, G A, Shabbeer, J, Yasuda, M, Eng, C M, Desnick, R J

    Published in Journal of human genetics (01-04-2001)
    “…Fabry disease, an X-linked inborn error of glycosphingolipid catabolism, results from the deficient activity of the lysosomal exoglycohydrolase,…”
    Get full text
    Journal Article
  13. 13
  14. 14
  15. 15

    Determination of a cyclooxygenase II inhibitor in human plasma by capillary gas chromatography with mass spectrometric detection by Dru, J.D.-Y., Chavez-Eng, C.M., Constanzer, M.L., Matuszewski, B.K.

    “…Sensitive methods based on capillary gas chromatography (GC) with mass spectrometric (MS) detection in a selected-ion monitoring mode (SIM) for the…”
    Get full text
    Journal Article
  16. 16

    Common mutations in the phosphofructokinase-M gene in Ashkenazi Jewish patients with glycogenesis. VII: And their population frequency by SHERMAN, J. B, RABEN, N, NICASTRI, C, ARGOV, Z, NAKAJIMA, H, ADAMS, E. M, ENG, C. M, COWAN, T. M, PLOTZ, P. H

    Published in American journal of human genetics (01-08-1994)
    “…Phosphofructokinase (PFK) catalyzes the rate-limiting step of glycolysis. Deficiency of the muscle enzyme is manifested by exercise intolerance and a…”
    Get full text
    Journal Article
  17. 17

    Nature and frequency of mutations in the [alpha]-galactosidase A gene that cause Fabry disease by Eng, C.M., Resnick-Silverman, L.A., Niehaus, D.J., Astrin, K.H., Desnick, R.J.

    Published in American journal of human genetics (01-12-1993)
    “…To determine the nature and frequency of the molecular lesions causing the classical and milder-variant Fabry phenotypes, and for precise carrier detection in…”
    Get full text
    Journal Article
  18. 18

    Phenotype/genotype correlations in Gaucher disease type 1 : clinical and therapeutic implications by SIBILLE, A, ENG, C. M, KIM, S.-J, PASTORES, G, GRABOWSKI, G. A

    Published in American journal of human genetics (01-06-1993)
    “…Gaucher disease is the most frequent lysosomal storage disease and the most prevalent genetic disease among Ashkenazi Jews. Gaucher disease type 1 is…”
    Get full text
    Journal Article
  19. 19

    Determination of Rofecoxib (MK-0966), a cyclooxygenase-2 inhibitor, in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection by Chavez-Eng, C.M, Constanzer, M.L, Matuszewski, B.K

    “…A method for the determination of 4-(4-methanesulfonylphenyl)-3-phenyl-5H-furan-2-one (Rofecoxib, Vioxx, MK-0966, I) a cyclooxygenase-2 inhibitor, in human…”
    Get full text
    Journal Article
  20. 20